Karyopharm Therapeutics (KPTI) Upgraded to “Sell” at ValuEngine

Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Thursday.

Other analysts have also recently issued research reports about the company. Jefferies Group reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Robert W. Baird reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, December 12th. BidaskClub upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. Karyopharm Therapeutics presently has an average rating of “Buy” and a consensus target price of $17.33.

Karyopharm Therapeutics (NASDAQ KPTI) traded down $0.62 during trading on Thursday, reaching $13.06. The company had a trading volume of 327,683 shares, compared to its average volume of 216,516. The stock has a market cap of $646.90, a PE ratio of -4.93 and a beta of 4.11. Karyopharm Therapeutics has a 1 year low of $7.48 and a 1 year high of $14.63.

In other Karyopharm Therapeutics news, insider Sharon Shacham sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $12.50, for a total value of $125,000.00. Following the sale, the insider now directly owns 723,510 shares of the company’s stock, valued at approximately $9,043,875. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Christopher Brett Primiano sold 27,042 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $10.28, for a total value of $277,991.76. Following the completion of the sale, the senior vice president now directly owns 11,381 shares in the company, valued at $116,996.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,542 shares of company stock worth $819,692. 14.71% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the business. Citadel Advisors LLC boosted its stake in Karyopharm Therapeutics by 51.1% in the 4th quarter. Citadel Advisors LLC now owns 54,308 shares of the company’s stock worth $521,000 after buying an additional 18,378 shares during the last quarter. Virtus Fund Advisers LLC acquired a new stake in Karyopharm Therapeutics in the 4th quarter worth about $355,000. Wells Fargo & Company MN boosted its stake in Karyopharm Therapeutics by 18.8% in the 4th quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock worth $298,000 after buying an additional 4,902 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at about $115,000. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of Karyopharm Therapeutics by 7.1% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 150,289 shares of the company’s stock valued at $1,443,000 after purchasing an additional 9,929 shares in the last quarter. 58.02% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Karyopharm Therapeutics (KPTI) Upgraded to “Sell” at ValuEngine” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/11/karyopharm-therapeutics-kpti-upgraded-to-sell-at-valuengine.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply